We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Salarius Pharmaceuticals Inc (SLRX) USD0.0001

Sell:$0.61 Buy:$0.66 Change: $0.011 (1.64%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.011 (1.64%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
Change: $0.011 (1.64%)
Market closed |  Prices as at close on 1 March 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing effective treatments for cancers with unmet medical needs. It is developing treatments for cancers caused by dysregulated gene expression. The Company’s product portfolio includes seclidemstat, which is being studied as a potential treatment for pediatric cancers, sarcomas and other cancers with limited treatment options. The Company's pipeline consists of two primary compounds: SP-3164, a small-molecule protein degrader, and seclidemstat (SP-2577), a small-molecule inhibitor. SP-3164 is a next-generation cereblon-binding molecular glue (MG). SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold. The molecule was discovered using structure-based computational screening coupled with chemical screening.

Contact details

2450 Holcombe Blvd Ste J-608
United States
+1 (617) 8741821

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.55 million
Shares in issue:
3.94 million
United States
US dollar

Key personnel

  • David Arthur
    President, Chief Executive Officer, Director
  • Mark Rosenblum
    Chief Financial Officer, Executive Vice President - Finance

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.